Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 · kind B2 · utility
1Cited by
50References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 30, 2005 |
| Grant date | Dec 27, 2011 |
| Priority date | — |
| Expiry date | Mar 6, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative and a disintegrating agent is herein disclosed and described. The dosage formulation exhibits a significant increase in bioavailability of the thiazolidinedione derivative component compared to conventional immediate release dosage forms containing only a thiazolidinedione derivative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.